NCT04459663Unknown2 期
A Single-arm, Single-center, Phase II Clinical Study to Investigate the Efficacy and Safety of JS001 Combined With Axitinib in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) With Negative Driving Gene After First-line Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- Li Zhang, MD
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- To evaluate the antitumor activity of Toripalimab injection (JS001) combined with Axitinib
研究概览
简要总结
This is a phase II, open, single-center clinical study to evaluate the efficacy and safety of JS001 combined with Axitinib in the treatment of advanced non-small cell lung cancer without activated EGFR mutation, ALK fusion and ROS fusion after or during first-line chemotherapy. About 50 subjects will be included in this study and will be treated with JS001 combined with acitinib. Each cycle is 21 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed the informed consent form (ICF);
- •Recurrent or advanced stage Ⅲ B or IV non-small cell lung cancer tested for EGFR mutation and ALK, ROS1 fusion gene, and all the driving gene was negative.
- •At least one measurable lesion (according to RECIST 1.1);
- •Failure of previous first-line standard chemotherapy:
- •Patients who agreed to provide previously stored tumor tissue specimens or fresh biopsies of tumor lesions
- •Age 18-75 years old, regardless of gender;
- •ECOG score 0-1;
- •Expected survival time ≥ 3 months;
- •Laboratory test value must show enough organ function
排除标准
- •Tumor histology or cytological pathology confirmed the presence of small cell lung cancer components, or sarcomatoid lesions;
- •Those who did not have a driving gene test;
- •Investigator believed that there was a clear bleeding tendency
- •Subjects who are currently participating in and receiving treatment in other studies, less than 4 weeks
- •Patients who had previously received second-line or more systemic chemotherapy for advanced NSCLC;
- •Patients who had received hematopoietic stimulating factors, within one week before the start of the study.
- •Uncontrollable or symptomatic hypercalcemia
- •Within 6 months before receiving the study treatment, they received chest (lung) radiotherapy > 30Gy, or received radiotherapy within 4 weeks or radiopharmaceuticals within 8 weeks, except for local palliative radiotherapy for bone metastases.
- •The adverse reactions of previous antineoplastic therapy have not yet recovered to CTCAE 5.0 grade ≤ 1 (except alopecia);
- •Major surgery or radiotherapy has been performed within 4 weeks before joining the group or has not yet fully recovered from the previous operation
- •Known active central nervous system (CNS) metastasis and / or cancerous meningitis;
- •Spinal cord compression without radical treatment of surgery and / or radiotherapy;
- •Uncontrolled tumor-related pain;
- •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage ;
- •Evidence of active pneumonia was found;
- •Clinically uncontrolled active infections;
- •Uncontrollable major seizures or superior vena cava syndrome;
- •Past or present co-existence of other malignant tumors;
- •Liver diseases known to be of clinical significance;
- •Those who have previously used any anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody or anti-CTLA-4 antibody and Axitinib;
- •Patients with active tuberculosis (TB);
- •Patients with any active autoimmune disease or history of autoimmune disease;
- •Any anti-infective vaccine;
- •Known (HIV) infection of human immunodeficiency virus;
- •The researchers believe that it can affect study compliance;
- •Patients who received systemic immunosuppressive drugs within the first 4 weeks of the first day of the first cycle;
- •History of severe allergy, anaphylaxis or other hypersensitivity to chimeric or humanized antibodies or fusion proteins;
- •Those who are known to be allergic to biological drugs;
- •Those who are known to be allergic to acitinib;
- •Patients with a history of arterial or venous thromboembolism;
- •Known hereditary or acquired bleeding and thrombotic tendencies;
- •Patients who have previously received allogeneic stem cell or parenchyma organ transplantation;
- •Pregnant or lactating women or women of childbearing age who were positive for serum pregnancy test before taking the drug for the first time
研究组 & 干预措施
JS001 combined with Axitinib
Experimental
JS001 combined with Axitinib in the treatment of advanced non-small cell lung cancer without activated EGFR mutation, ALK fusion and ROS fusion after or during first-line chemotherapy
干预措施: Toripalimab injection combine with Axitinib (Drug)
结局指标
主要结局
To evaluate the antitumor activity of Toripalimab injection (JS001) combined with Axitinib
时间窗: From date of randomization untiL intolerable toxicity, or investigators determined subjects could not benefit from the study treatment, or subjects withdrew their informed consent or died, or the the drug had been used continuously for 2 years.
The objective tumor reponse rate ((ORR)) evaluated by the investigator based on the solid tumor efficacy evaluation criteria (RECIST 1.1)
次要结局
- To evaluate the efficacy of JS001 combined with Axitinib(From date of randomization untiL intolerable toxicity, or investigators determined subjects could not benefit from the study treatment, or subjects withdrew their informed consent or died, or the the drug had been used continuously for 2 years.)
- To evaluate the safety of JS001 combined with Axitinib(From date of randomization untiL intolerable toxicity, or investigators determined subjects could not benefit from the study treatment, or subjects withdrew their informed consent or died, or the the drug had been used continuously for 2 years.)
- To evaluate the correlation between programmed death receptor-ligand 1 (PD-L1) expression and anti-tumor response in tumor tissues.(From date of randomization untiL intolerable toxicity, or investigators determined subjects could not benefit from the study treatment, or subjects withdrew their informed consent or died, or the the drug had been used continuously for 2 years.)
研究者
Li Zhang, MD
Principal Investigator
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
招募中
2 期
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung CancerSmall-cell Lung CancerNCT04951947Hunan Province Tumor Hospital30
进行中（未招募）
2 期
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell LymphomaMantle Cell LymphomaNCT04718883Shanghai Ming Ju Biotechnology Co., Ltd.59
Unknown
2 期
Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal CancerRefractory Metastatic Digestive System CarcinomaPrimary Peritoneal CancerNCT05030246Peking University72
Unknown
2 期
Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic CancerMetastatic Pancreatic CancerNCT03929094Fudan University120
进行中（未招募）
2 期
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic CancerPancreatic NeoplasmsNCT05481476Sun Yat-sen University32